Current disease status-Recurrent cancer-Metastatic recurrence Page 2 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer-Metastatic recurrence Posts on Medivizor

The effectiveness and cardiac safety of CMF plus trastuzumab in HER2-positive metastatic breast cancer

Posted by on Apr 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the safety and effectiveness of treatment with combination cyclophosphamide (Cytoxan), methotrexate (Otrexup) and 5-fluoruoracil (Efudex) (CMF) plus trastuzumab (Herceptin) in HER2-positive metastatic breast cancer (MBC, cancer that has spread beyond the breast) patients. CMF plus trastuzumab (CMF+T) was found to...

Read More

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

Comparing the safety of surgery options for patients with peritoneal metastasis

Posted by on Jan 11, 2017 in Colorectal cancer | 0 comments

In a nutshell This study investigated the safety of hyperthermic intraperitoneal chemotherapy (HIPEC) and surgery in colon cancer patients with peritoneal metastasis (PM). Researchers reported that HIPEC and surgery was associated with an increased risk of complications. Some background When colon cancer spreads to the abdominal lining (known as...

Read More

Panitumumab is associated with improved survival in metastatic colorectal cancer without KRAS or RAS mutations

Posted by on Dec 19, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of panitumumab (Vectibix) in overall survival of patients with metastatic colorectal cancer without a KRAS or RAS mutation. Researchers suggested that panitumumab significantly improved survival in these patients.  Some background Panitumumab is a therapy that targets a...

Read More

Secondary hormone therapies: Should abiraterone or enzalutamide be administered first?

Posted by on Dec 19, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether abiraterone (Zytiga) or enzalutamide (Xtandi) should be administered first in the treatment of metastatic castration-resistant prostate cancer. Authors report preliminary evidence for reduced disease progression when administering abiraterone before enzalutamide compared to the reverse sequence. A significant...

Read More

Early use of chemotherapy in metastatic prostate cancer – an overview of current evidence

Posted by on Nov 27, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined evidence for the benefits of adding chemotherapy early to hormone therapy for metastatic prostate cancer. Authors concluded that early evidence indicates a survival benefit with the addition of chemotherapy for metastatic prostate cancer. Some background Androgen deprivation therapy (ADT) is a type of hormone...

Read More

The duration of primary hormone therapy does not limit the effectiveness of secondary hormone therapy with abiraterone

Posted by on Nov 14, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether the duration of primary (first round) hormone therapy impacts abiraterone (Zytiga) treatment for metastatic castration-resistant prostate cancer (mCRPC). Researchers concluded that the benefits of abiraterone were not dependent on the duration of primary hormone therapy. Some background Androgen...

Read More

Cetuximab improved survival compared to bevacizumab when combined with FOLFIRI in metastatic colorectal cancer

Posted by on Oct 24, 2016 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of the chemotherapy FOLFIRI plus cetuximab (Erbitux) and FOLFIRI plus bevacizumab (Avastin). Researchers suggested that FOLFIRI plus cetuximab is associated with a higher effectiveness in treating metastatic (spread to other parts of the body) colorectal cancers. Some background FOLFIRI is...

Read More

Secondary hormone therapy with enzalutamide also effective for metastatic prostate cancer affecting the lung or liver

Posted by on Oct 9, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effects of enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC) that has spread to the lungs and/or liver. Researchers reported that enzalutamide is safe and effective for men with mCRPC affecting the lung or liver. Some background When prostate cancer spreads outside of...

Read More